References
- Rao R, Shields CL. Overview and classification of conjunctival and corneal tumors. In: Chaugule SS, Honavar SG, and Finger PT, editors. Surgical ophthalmic oncology: a collaborative open access reference. Cham, CH: Springer Nature Switzerland AG;2019. p. 69–74. doi:https://doi.org/10.1007/978-3-030-18757-6_6.
- Shields CL, Alset AE, Boal NS, Casey MG, Knapp AN, Sugarman JA, Schoen MA, Gordon PS, Douglass AM, Sioufi K, et al. Conjunctival tumors in 5002 cases. comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen Lecture. Am J Ophthalmol. 2017;173:106–33. doi:https://doi.org/10.1016/j.ajo.2016.09.034.
- Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol. 2009;27(1):122–33. doi:https://doi.org/10.1016/j.clindermatol.2008.09.010.
- Brownstein S. Malignant melanoma of the conjunctiva. Cancer Control. 2004;11(5):310–16. doi:https://doi.org/10.1177/107327480401100505.
- De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77(10):624–30. doi:https://doi.org/10.1136/bjo.77.10.624.
- Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6:1230–44.
- McCartney AC. Pathology of ocular melanomas. Br Med Bull. 1995;51(3):678–93. doi:https://doi.org/10.1093/oxfordjournals.bmb.a072986.
- Mudhar HS, Rennie IG. Local conjunctival metastases from primary conjunctival melanoma: clinico-pathological correlation and implications. Br J Ophthalmol. 2013;97(1):33–39. doi:https://doi.org/10.1136/bjophthalmol-2011-301334.
- Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42(4):321–50. doi:https://doi.org/10.1016/s0039-6257(97)00122-7.
- Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996;234(9):569–72. doi:https://doi.org/10.1007/BF00448801.
- Shields CL, Fasiuddin AF, Fasiudden A, Mashayekhi A, Shields JA. Conjunctival nevi: clinical features and natural course in 410 consecutive patients. Arch Ophthalmol. 2004;122(2):167–75. doi:https://doi.org/10.1001/archopht.122.2.167.
- Shields CL, Shields JA, Gündüz K, Cater, J, Mercado, G V, Gross, N, Lally, B . Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118(11):1497–507. doi:https://doi.org/10.1001/archopht.118.11.1497.
- Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Lally SE, Mashayekhi A, Shields JA. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389–395.e1-2. doi:https://doi.org/10.1016/j.ophtha.2010.06.021.
- Shields JA, Shields CL, Mashayekhi A, Marr BP, Benavides R, Thangappan A, Phan L, Eagle RC. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture. Ophthalmology. 2008;115(3):511–519.e2. doi:https://doi.org/10.1016/j.ophtha.2007.07.003.
- Pacheco RR, Yaghy A, Dalvin LA, Vaidya S, Perez AL, Lally SE, Shields JA, Shields CL. Conjunctival melanoma: outcomes based on tumour origin in 629 patients at a single ocular oncology centre. Eye (Lond). 2021 March 26. Published online. doi:https://doi.org/10.1038/s41433-021-01508-y.
- Inskip PD, Devesa SS, Fraumeni JF. Trends in the incidence of ocular melanoma in the United States, 1974–1998. Cancer Causes Control. 2003;14(3):251–57. doi:https://doi.org/10.1023/A:1023684502638.
- Yu G-P, Hu D-N, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135(6):800–06. doi:https://doi.org/10.1016/S0002-9394(02)02288-2.
- Hu D-N, Yu G, McCormick SA, Finger PT. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol. 2008;145(3):418–23. doi:https://doi.org/10.1016/j.ajo.2007.10.022.
- Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–78. doi:https://doi.org/10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g.
- Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001;108(11):2101–05. doi:https://doi.org/10.1016/s0161-6420(01)00782-5.
- Grimes JM, Shah NV, Samie FH, Carvajal RD, Marr BP. Conjunctival melanoma: current treatments and future options. Am J Clin Dermatol. 2020 January 21;21(3):371–81. Published online. doi:https://doi.org/10.1007/s40257-019-00500-3.
- Koç İ, Kıratlı H. Current management of conjunctival melanoma part 2: treatment and future directions. Turk J Ophthalmol. 2020;50(6):362–70. doi:https://doi.org/10.4274/tjo.galenos.2020.22567.
- Damato B, Coupland SE. An audit of conjunctival melanoma treatment in Liverpool. Eye (Lond). 2009;23(4):801–09. doi:https://doi.org/10.1038/eye.2008.154.
- Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78(4):252–59. doi:https://doi.org/10.1136/bjo.78.4.252.
- Abdulwahab A, Sykes J, Kamel-Reid S, Chang H, Brandwein JM. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012;118(16):3962–67. doi:https://doi.org/10.1002/cncr.26735.
- Laíns I, Bartosch C, Mondim V, Healy B, Kim IK, Husain D, Miller JW. Second primary neoplasms in patients with uveal melanoma: a SEER database analysis. Am J Ophthalmol. 2016;165:54–64. doi:https://doi.org/10.1016/j.ajo.2016.02.022.
- Tamboli D, Topham A, Singh N, Singh AD. Retinoblastoma: a SEER dataset evaluation for treatment patterns, survival, and second malignant neoplasms. Am J Ophthalmol. 2015;160(5):953–58. doi:https://doi.org/10.1016/j.ajo.2015.07.037.
- Hendrix M. Second primary malignancies in patients with conjunctival melanoma. Invest Ophthalmol Vis Sci. 2003;44:2430–2430.
- Surveillance, epidemiology, and end results (SEER) program. SEER*Stat Database: incidence - SEER research data, 18. Registries (excl AK), Nov 2020 Sub (2000-2018), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. www.seer.cancer.gov.
- Begg CB. Methodological and statistical considerations in the study of multiple primary cancers. In: Multiple primary cancers Neugut, AI, Meadows, AT, and Robinson, E. Philadelphia (PA): Lippincott Williams and Wilkins; 1999. p. 13–26.
- ICD-O-3 Site Codes | SEER training. [accessed 2020 May 5]. https://training.seer.cancer.gov/biliary/abstract-code-stage/codes.html.
- Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, et al. NCCN guidelines insights: uveal melanoma, version 1.2019: featured updates to the NCCN guidelines. J Nat Comprehensive Cancer Network. 2020;18(2):120–31. doi:https://doi.org/10.6004/jnccn.2020.0007.
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. doi:https://doi.org/10.1038/nature00766.
- Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14(6):449–52. doi:https://doi.org/10.1097/00008390-200412000-00003.
- Gear H, Williams H, Kemp EG, Roberts F. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2004;45(8):2484–88. doi:https://doi.org/10.1167/iovs.04-0093.
- Pinto Torres S, André T, Gouveia E, Costa L, Passos MJ. Systemic treatment of metastatic conjunctival melanoma. Case Rep Oncol Med. 2017:2017. doi:https://doi.org/10.1155/2017/4623964.
- Rossi E, Maiorano BA, Pagliara MM, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, et al. Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma. Front Oncol. 2019;9:9. doi:https://doi.org/10.3389/fonc.2019.00232.
- Dagi Glass LR, Lawrence DP, Jakobiec FA, Freitag SK. Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors. Ophthal Plast Reconstr Surg. 2017;33(5):e114. doi:https://doi.org/10.1097/IOP.0000000000000833.
- Sample A, He -Y-Y. Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed. 2018;34(1):13–24. doi:https://doi.org/10.1111/phpp.12329.
- Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene. 2003;22(20):3099–112. doi:https://doi.org/10.1038/sj.onc.1206450.
- Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666–74. doi:https://doi.org/10.1038/jid.2008.423.
- Kosary CL, Altekruse SF, Ruhl J, Lee R, Dickie L. Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014;120(Suppl 23):3807–14. doi:https://doi.org/10.1002/cncr.29050.
- Rivolta C, Royer-Bertrand B, Rimoldi D, Schalenbourg A, Zografos L, Leyvraz S, Moulin A. UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation. J Hum Genet. 2016;61(4):361–62. doi:https://doi.org/10.1038/jhg.2015.152.
- Mundra PA, Dhomen N, Rodrigues M, Mikkelsen LH, Cassoux N, Brooks K, Valpione S, Reis-Filho JS, Heegaard S, Stern M-H, et al. Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nat Commun. 2021;12(1):259. doi:https://doi.org/10.1038/s41467-020-20432-5.
- Hurst EA, Harbour JW, Cornelius LA. Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol. 2003;139(8):1067–73. doi:https://doi.org/10.1001/archderm.139.8.1067.
- Silva JH, de Sá BCS, de Ávila ALR, Landman G, Neto JPD. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo). 2011;66(3):493–99. doi:https://doi.org/10.1590/S1807-59322011000300023.
- Vora GK, Demirci H, Marr B, Mruthyunjaya P. Advances in the management of conjunctival melanoma. Surv Ophthalmol. 2017;62(1):26–42. doi:https://doi.org/10.1016/j.survophthal.2016.06.001.
- Sun EC, Fears TR, Goedert JJ. Epidemiology of squamous cell conjunctival cancer. Cancer Epidemiol Biomarkers Prevent. 1997;6:73–77.
- Caso ER, Marcos AA, Morales M, Belfort RN. Simultaneous squamous cell carcinoma and malignant melanoma of the conjunctiva in a teenager with xeroderma pigmentosum: case report. Indian J Ophthalmol. 2019;67(7):1190–92. doi:https://doi.org/10.4103/ijo.IJO_1106_18.
- Halkud R, Shenoy AM, Naik SM, Chavan P, Sidappa KT, Biswas S. Xeroderma pigmentosum: clinicopathological review of the multiple oculocutaneous malignancies and complications. Indian J Surg Oncol. 2014;5(2):120–24. doi:https://doi.org/10.1007/s13193-014-0307-6.
- Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3(1):33–42. doi:https://doi.org/10.1038/ncpgasthep0389.
- Blechacz BRA, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12(1):131–50. doi:https://doi.org/10.1016/j.cld.2007.11.003. ix
- Tyson GL, El-Serag HB. Risk factors of cholangiocarcinoma. Hepatology. 2011;54(1):173–84. doi:https://doi.org/10.1002/hep.24351.
- Matsumoto M, Secrest A, Anderson A, Saul MI, Ho J, Kirkwood JM, Ferris LK. Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol. 2018;78(4):701–709.e1. doi:https://doi.org/10.1016/j.jaad.2017.11.033.
- Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol. 1999;41(5 I):738–45. doi:https://doi.org/10.1016/S0190-9622(99)70010-1.
- Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The surveillance, epidemiology and end results (SEER) program and pathology: towards strengthening the critical relationship. Am J Surg Pathol. 2016;40(12):e94–e102. doi:https://doi.org/10.1097/PAS.0000000000000749.
- Jiang S, Jiang H, Sun L, Luo Z. Risk of second primary malignancies of adolescent and young adult patients with germ cell cancer: a US population-based analysis. Curr Probl Cancer. 2020 August 29;45(2):100641. Published online. doi:https://doi.org/10.1016/j.currproblcancer.2020.100641.
- Zhang B, Guo K, Zheng X, Sun L, Shen M, Ruan S. Risk of second primary malignancies in colon cancer patients treated with colectomy. Front Oncol. 2020;10:1154. doi:https://doi.org/10.3389/fonc.2020.01154.
- Li X, Guo K, Feng Y, Guo Y. Analysis of chemotherapy effect on the second primary malignancy for head and neck cancer patients by a nomogram based on SEER database. Cancer Med. 2020;9(21):8029–42. doi:https://doi.org/10.1002/cam4.3442.